Tobacco, nicotine and cotinine

For memory, neurological, and psychiatric disorders

V. Echeverria, Rajeev Prabhakar, R. Zeitlin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Epidemiological studies have associated tobacco consumption with a lower incidence of Alzheimer's disease (AD) and Parkinson's disease (PD). The neuroprotective effect of tobacco has been mainly attributed to the stimulation by nicotine of the α7 nicotinic acetylcholine receptors (nAChRs), which are implicated in neuronal survival, attention, and memory. A reduction in cholinergic function including lower levels of the expression of nAChRs in the hippocampus correlates with memory impairment in AD and schizophrenia. Although nicotine improves memory, sensory gating, and attention, its toxicity and undesired effects such as negative cardiovascular effects have terminated its therapeutic applications. Interestingly, its main metabolite cotinine shows similar neuroprotective and mnemonic properties but has a ten-fold longer half-life than nicotine and a good safety profile in humans. In neurodegenerative conditions including AD and PD, the accumulation of aggregated forms of the P-amyloid peptide correlates with cognitive impairment. Cotinine has been shown to reduce Ap aggregation in vitro. Additionally, since cotinine is a weak agonist of the nAChRs, we postulate that cotinine improves neuronal survival and memory at least in part by acting as a positive modulator of the α7 nAChRs. The potentiation of α7 nAChRs by cotinine can be beneficial in a broad range of neurological disorders such as schizophrenia, AD, attention-deficit hyperactivity disorder, and PD in which the modulation of these receptors can ameliorate working memory and attention. Based on actual evidence and these ideas, the relevance and potential therapeutic use of cotinine in several neurological disorders are discussed in this chapter. "Only do not forget, if I wake up crying it's only because in my dream I'm a lost child hunting through the leaves of the night for your hands...." - Pablo Neruda [1].

Original languageEnglish
Title of host publicationWorking Memory: Capacity, Developments and Improvement Techniques
PublisherNova Science Publishers, Inc.
Pages349-371
Number of pages23
ISBN (Print)9781617619809
StatePublished - Feb 1 2011

Fingerprint

Cotinine
Nervous System Diseases
Nicotine
Nicotinic Receptors
Tobacco
Psychiatry
Alzheimer Disease
Parkinson Disease
Schizophrenia
Sensory Gating
Crying
Tobacco Use
Neuroprotective Agents
Therapeutic Uses
Attention Deficit Disorder with Hyperactivity
Short-Term Memory
Amyloid
Cholinergic Agents
Half-Life
Epidemiologic Studies

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Echeverria, V., Prabhakar, R., & Zeitlin, R. (2011). Tobacco, nicotine and cotinine: For memory, neurological, and psychiatric disorders. In Working Memory: Capacity, Developments and Improvement Techniques (pp. 349-371). Nova Science Publishers, Inc..

Tobacco, nicotine and cotinine : For memory, neurological, and psychiatric disorders. / Echeverria, V.; Prabhakar, Rajeev; Zeitlin, R.

Working Memory: Capacity, Developments and Improvement Techniques. Nova Science Publishers, Inc., 2011. p. 349-371.

Research output: Chapter in Book/Report/Conference proceedingChapter

Echeverria, V, Prabhakar, R & Zeitlin, R 2011, Tobacco, nicotine and cotinine: For memory, neurological, and psychiatric disorders. in Working Memory: Capacity, Developments and Improvement Techniques. Nova Science Publishers, Inc., pp. 349-371.
Echeverria V, Prabhakar R, Zeitlin R. Tobacco, nicotine and cotinine: For memory, neurological, and psychiatric disorders. In Working Memory: Capacity, Developments and Improvement Techniques. Nova Science Publishers, Inc. 2011. p. 349-371
Echeverria, V. ; Prabhakar, Rajeev ; Zeitlin, R. / Tobacco, nicotine and cotinine : For memory, neurological, and psychiatric disorders. Working Memory: Capacity, Developments and Improvement Techniques. Nova Science Publishers, Inc., 2011. pp. 349-371
@inbook{5662f00c6e3642ddb6647a38a5c9fd76,
title = "Tobacco, nicotine and cotinine: For memory, neurological, and psychiatric disorders",
abstract = "Epidemiological studies have associated tobacco consumption with a lower incidence of Alzheimer's disease (AD) and Parkinson's disease (PD). The neuroprotective effect of tobacco has been mainly attributed to the stimulation by nicotine of the α7 nicotinic acetylcholine receptors (nAChRs), which are implicated in neuronal survival, attention, and memory. A reduction in cholinergic function including lower levels of the expression of nAChRs in the hippocampus correlates with memory impairment in AD and schizophrenia. Although nicotine improves memory, sensory gating, and attention, its toxicity and undesired effects such as negative cardiovascular effects have terminated its therapeutic applications. Interestingly, its main metabolite cotinine shows similar neuroprotective and mnemonic properties but has a ten-fold longer half-life than nicotine and a good safety profile in humans. In neurodegenerative conditions including AD and PD, the accumulation of aggregated forms of the P-amyloid peptide correlates with cognitive impairment. Cotinine has been shown to reduce Ap aggregation in vitro. Additionally, since cotinine is a weak agonist of the nAChRs, we postulate that cotinine improves neuronal survival and memory at least in part by acting as a positive modulator of the α7 nAChRs. The potentiation of α7 nAChRs by cotinine can be beneficial in a broad range of neurological disorders such as schizophrenia, AD, attention-deficit hyperactivity disorder, and PD in which the modulation of these receptors can ameliorate working memory and attention. Based on actual evidence and these ideas, the relevance and potential therapeutic use of cotinine in several neurological disorders are discussed in this chapter. {"}Only do not forget, if I wake up crying it's only because in my dream I'm a lost child hunting through the leaves of the night for your hands....{"} - Pablo Neruda [1].",
author = "V. Echeverria and Rajeev Prabhakar and R. Zeitlin",
year = "2011",
month = "2",
day = "1",
language = "English",
isbn = "9781617619809",
pages = "349--371",
booktitle = "Working Memory: Capacity, Developments and Improvement Techniques",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Tobacco, nicotine and cotinine

T2 - For memory, neurological, and psychiatric disorders

AU - Echeverria, V.

AU - Prabhakar, Rajeev

AU - Zeitlin, R.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Epidemiological studies have associated tobacco consumption with a lower incidence of Alzheimer's disease (AD) and Parkinson's disease (PD). The neuroprotective effect of tobacco has been mainly attributed to the stimulation by nicotine of the α7 nicotinic acetylcholine receptors (nAChRs), which are implicated in neuronal survival, attention, and memory. A reduction in cholinergic function including lower levels of the expression of nAChRs in the hippocampus correlates with memory impairment in AD and schizophrenia. Although nicotine improves memory, sensory gating, and attention, its toxicity and undesired effects such as negative cardiovascular effects have terminated its therapeutic applications. Interestingly, its main metabolite cotinine shows similar neuroprotective and mnemonic properties but has a ten-fold longer half-life than nicotine and a good safety profile in humans. In neurodegenerative conditions including AD and PD, the accumulation of aggregated forms of the P-amyloid peptide correlates with cognitive impairment. Cotinine has been shown to reduce Ap aggregation in vitro. Additionally, since cotinine is a weak agonist of the nAChRs, we postulate that cotinine improves neuronal survival and memory at least in part by acting as a positive modulator of the α7 nAChRs. The potentiation of α7 nAChRs by cotinine can be beneficial in a broad range of neurological disorders such as schizophrenia, AD, attention-deficit hyperactivity disorder, and PD in which the modulation of these receptors can ameliorate working memory and attention. Based on actual evidence and these ideas, the relevance and potential therapeutic use of cotinine in several neurological disorders are discussed in this chapter. "Only do not forget, if I wake up crying it's only because in my dream I'm a lost child hunting through the leaves of the night for your hands...." - Pablo Neruda [1].

AB - Epidemiological studies have associated tobacco consumption with a lower incidence of Alzheimer's disease (AD) and Parkinson's disease (PD). The neuroprotective effect of tobacco has been mainly attributed to the stimulation by nicotine of the α7 nicotinic acetylcholine receptors (nAChRs), which are implicated in neuronal survival, attention, and memory. A reduction in cholinergic function including lower levels of the expression of nAChRs in the hippocampus correlates with memory impairment in AD and schizophrenia. Although nicotine improves memory, sensory gating, and attention, its toxicity and undesired effects such as negative cardiovascular effects have terminated its therapeutic applications. Interestingly, its main metabolite cotinine shows similar neuroprotective and mnemonic properties but has a ten-fold longer half-life than nicotine and a good safety profile in humans. In neurodegenerative conditions including AD and PD, the accumulation of aggregated forms of the P-amyloid peptide correlates with cognitive impairment. Cotinine has been shown to reduce Ap aggregation in vitro. Additionally, since cotinine is a weak agonist of the nAChRs, we postulate that cotinine improves neuronal survival and memory at least in part by acting as a positive modulator of the α7 nAChRs. The potentiation of α7 nAChRs by cotinine can be beneficial in a broad range of neurological disorders such as schizophrenia, AD, attention-deficit hyperactivity disorder, and PD in which the modulation of these receptors can ameliorate working memory and attention. Based on actual evidence and these ideas, the relevance and potential therapeutic use of cotinine in several neurological disorders are discussed in this chapter. "Only do not forget, if I wake up crying it's only because in my dream I'm a lost child hunting through the leaves of the night for your hands...." - Pablo Neruda [1].

UR - http://www.scopus.com/inward/record.url?scp=84892977788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892977788&partnerID=8YFLogxK

M3 - Chapter

SN - 9781617619809

SP - 349

EP - 371

BT - Working Memory: Capacity, Developments and Improvement Techniques

PB - Nova Science Publishers, Inc.

ER -